| Literature DB >> 33478285 |
Raheleh Tooyserkani1, Mohammad Javad Rasaee1, Mojgan Bandehpour2, Dennis W P M Löwik3.
Abstract
PD-L1 overexpression on tumour cells forms a protective shield against cytotoxic T-cell killing, which consequently leads to immune evasion. Engagement of PD-1 in tumour infiltrating T cells with PD-L1 results in an exhausted T-cell phenotype, thus preventing an effective immune response against tumour cells. In the present study, we employed phage display combinatorial peptide library to discover anti-PD-L1 peptides. The peptides discovered here, could computationally exhibit specific interactions with PD-L1 at residues with which PD-1 also interacts. Binding affinity and specificity of the peptides were examined by flow cytometry. Anti- tumour activity of peptides was also investigated using several cell-based assays. Surprisingly, we demonstrated that Pep-39 can inhibit PDL-1, and reduce MDA-MB-231, CT-26, and DU-145 cells survival. In co-culture experiments, Pep-39 restored proliferation of Jurkat cells cultured in the presence of MDA-MB-231 cells. In addition, Jurkat cells apoptosis was impeded, indicating blocking potential of Pep-39 against PD-1/PD-L1 interaction.Entities:
Keywords: Peptide; checkpoint inhibitor; phage display; programmed death ligand 1; survival
Mesh:
Substances:
Year: 2021 PMID: 33478285 DOI: 10.1080/1061186X.2021.1879087
Source DB: PubMed Journal: J Drug Target ISSN: 1026-7158 Impact factor: 5.121